raloxifene hydrochloride has been researched along with Cancer of Pancreas in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abualsunun, W; Ahmed, OAA; Aldawsari, HM; Alhakamy, NA; Badr-Eldin, SM; Eid, BG; El Sherbiny, GA; Fahmy, UA; Radwan, MF; Sayed, SRM | 1 |
| Bruns, CJ; Camaj, P; Hartmann, L; Hering, NA; Kreis, ME; Lee, LD; Liu, V; Müller, MH; Pozios, I; Seel, NN; Seeliger, H | 1 |
2 other study(ies) available for raloxifene hydrochloride and Cancer of Pancreas
| Article | Year |
|---|---|
Potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells.
Topics: bcl-2-Associated X Protein; Humans; Melitten; Pancreatic Neoplasms; Phospholipids; Raloxifene Hydrochloride | 2022 |
Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Cytokine Receptor gp130; Estrogen Receptor beta; Humans; Interleukin-6; Male; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Raloxifene Hydrochloride; Signal Transduction; STAT3 Transcription Factor; Time Factors; Xenograft Model Antitumor Assays | 2021 |